Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ADAT2 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-05 |
mRNA | GIPC1 | CTRPv2 | pan-cancer | AAC | -0.16 | 4e-05 |
mRNA | LINC00684 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | GPR143 | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
mRNA | MYB | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-05 |
mRNA | BCL2L2-PABPN1 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | AHCTF1 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | ANKRD17 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | NEDD4 | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
mRNA | EIF4EBP2 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |